Short answer
EyePoint, Inc. (EYPT) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $507,000 (down 90.5% year over year) with net income of −$94M.
Q2 2026 key financials · XBRL
- Revenue
- $507,000
- −90.5% YoY · −27.2% QoQ
- Net income
- −$94M
- −59.0% YoY · −11.4% QoQ
- Operating margin
- -19207.1%
- EPS (diluted)
- −$1.09
- −28.2% YoY · −10.1% QoQ
Source: XBRL data from the EyePoint, Inc. (EYPT) Q2 2026 10-Q on SEC EDGAR. USD.
EyePoint, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0.5M, down 90% YoY from $5.3M
- Net loss $94.5M vs $59.4M YoY; operating loss $97.4M vs $62.2M
- DURAVYU R&D spending $58.0M vs $37.3M, the largest program investment
- Cash, equivalents, and marketable securities $180.5M; funding expected into Q4 2027
- Operating cash outflow $142.9M vs $115.7M; ATM proceeds $19.6M net in six months
Risk Factors
- New litigation risk triggered by March 20, 2026 complaint against Ocular over alleged false or misleading DURAVYU statements
- Legal exposure increased after Ocular’s April 13, 2026 answer sought dismissal with prejudice and attorneys’ fees
- Regulatory-compliance risk reflected in July 2026 settlement and Corporate Integrity Agreement with HHS OIG and TRICARE
- Near-term market risk from volatile trading and low volume, potentially limiting desired liquidation timing and price
- Financial dilution risk from additional shares issued upon outstanding options, warrants, or stock-unit settlement
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other EyePoint, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.